Scotiabank analyst Sung Ji Nam last night initiated coverage of Olink with an Outperform rating and $27 price target. The analyst started coverage on nine companies in the life science tools and diagnostics space with a positive view on the sector. Olink is uniquely positioned to significantly capture share in the burgeoning high-throughput, high-plex proteomics market over the next several years, Ji Nam tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OLK:
- Olink initiated with an Outperform at Scotiabank
- Olink to participate in the 41st Annual JP Morgan Healthcare Conference
- Olink initiated with a Buy at Canaccord
- Maria Martin-Grau, at the University of Valencia, Spain is selected for the 2022 Novelties in Biomarkers award
- Olink to hold an investor day
